BioCytics Successfully Completes a Key Regulatory Milestone with Recent FDA INTERACT Meeting
BioCyticsis pleased to announce they successfully reached a regulatory milestone for de-risking clinical development plans with a productive FDA INTERACT meeting during which they discussed manufacturing immune cell therapies at the point of care. https://mma.prnewswire.com/media/2572302/BioCytics_hires_Master_logo_long_Logo.jpg This INTERACT (INitial Targeted Engagement for Regulatory Advice on CBER/CDER ProducTs) meeting is a first step ingetting feedback from the […]